Clinical Trial Update: Dose-Ranging Study of AVI-4658 to Induce Dystrophin Expression in Selected Duchenne Muscular Dystrophy (DMD) Patients [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 dose-ranging study of AVI-4658 (eteplirsen) to induce dystrophin expression in Duchenne muscular dystrophy patients; results were posted in 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Duchenne Muscular Dystrophy

Drugs mentioned

• EXONDYS 51 (eteplirsen)

Snippet

Sponsor: Sarepta Therapeutics, Inc. | Conditions: Duchenne Muscular Dystrophy | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2015-10-06